Cargando…

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol

INTRODUCTION: Belimumab, an anti-B-lymphocyte-stimulator antibody, is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Rituximab, a B cell-depleting anti-CD20 antibody, remains in the SLE treatment armamentarium despite failed trials in lupus nephritis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Y K Onno, Bruce, Ian N, Diamond, Betty, Furie, Richard A, van Vollenhoven, Ronald F, Gordon, David, Groark, James, Henderson, Robert B, Oldham, Mary, Tak, Paul P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475247/ https://www.ncbi.nlm.nih.gov/pubmed/30898822 http://dx.doi.org/10.1136/bmjopen-2018-025687

Ejemplares similares

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
por: Kastbom, Alf, et al.
Publicado: (2012)

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
por: Brunner, Hermine I, et al.
Publicado: (2021)

Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects
por: Struemper, Herbert, et al.
Publicado: (2015)

SLE and Serum Complement: Causative, Concomitant or Coincidental?
por: Sandhu, Vaneet, et al.
Publicado: (2018)

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
por: Lokhandwala, Tasneem, et al.
Publicado: (2021)

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care
por: Bruce, I N, et al.
Publicado: (2016)

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial
por: Dirikgil, Ebru, et al.
Publicado: (2022)

Treatment patterns and control of hypertension in systemic lupus erythematosus (SLE): a cross-sectional study
por: Liu, Jia Li, et al.
Publicado: (2021)

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
por: van Vollenhoven, Ronald F, et al.
Publicado: (2018)

Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
por: Jones, Alexis, et al.
Publicado: (2019)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Looks Can Be Deceiving: A Case Report on Multicentric Reticulohistiocytosis Successfully Treated with Rituximab
por: Lim, Khin, et al.
Publicado: (2017)

Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
por: Furuta, Shunsuke, et al.
Publicado: (2017)

Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
por: Sheikh, Saira Z., et al.
Publicado: (2016)

Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

Vagus nerve stimulation as a novel treatment for systemic lupus erythematous: study protocol for a randomised, parallel-group, sham-controlled investigator-initiated clinical trial, the SLE-VNS study
por: Zinglersen, Amanda Hempel, et al.
Publicado: (2022)

Are dietary vitamin D, omega-3 fatty acids and folate associated with treatment results in patients with early rheumatoid arthritis? Data from a Swedish population-based prospective study
por: Lourdudoss, Cecilia, et al.
Publicado: (2017)

The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis
por: Alzahrani, Ziyad, et al.
Publicado: (2023)

Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study
por: Alvarez-Madrazo, Samantha, et al.
Publicado: (2019)

Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database
por: Bhoi, Peter, et al.
Publicado: (2017)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
por: Struemper, Herbert, et al.
Publicado: (2017)

This, This Is Bliss
Publicado: (1882)

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus
por: Doria, A, et al.
Publicado: (2018)

SLE - Rituximab in lupus
por: Eisenberg, Robert
Publicado: (2003)

Clinical response to belimumab in academic clinical practices
por: Reddy, Arthi, et al.
Publicado: (2014)

Shadows of Bliss
por: CERN. Geneva, et al.
Publicado: (1972)

The Bliss of Madness
por: Jameson, Richard
Publicado: (1972)

Prohibited Bliss
Publicado: (1886)

Bliss & Sharp
Publicado: (1868)

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients
por: Capdevila, O., et al.
Publicado: (2023)

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
por: Stohl, William, et al.
Publicado: (2017)

Understanding Heterogeneity in Patients’ Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis
por: Hsiao, Betty, et al.
Publicado: (2023)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
por: Plüß, Marlene, et al.
Publicado: (2020)

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome
por: Mariette, Xavier, et al.
Publicado: (2022)

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients
por: Escalera, Carlos Rodríguez, et al.
Publicado: (2022)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fc1jgt579nuuso6d27h433p1fb